Charles Riv Labs Intl Inc Stock Price, News & Analysis

Charles River Laboratories International, Inc. (NYSE: CRL) will announce its Q4 2022 and full-year 2022 financial results along with guidance for 2023 on February 22, before market opening. A conference call is scheduled for 8:30 a.m. ET on the same day to discuss the results. Investors can access the live webcast through the Investor Relations section of the company's website. Charles River provides critical services and products to pharmaceutical, biotechnology companies, and academic institutions worldwide, aiming to enhance the research and development of new therapies.

Charles River Laboratories (NYSE: CRL) announced the acquisition of SAMDI Tech, Inc. for $50 million, enhancing its drug discovery capabilities through SAMDI's proprietary mass spectrometry technology. This strategic move, marking the culmination of a partnership that began in 2018, aims to improve high-throughput screening (HTS) solutions, accelerating drug discovery timelines and reducing associated costs. The technology offers significant advantages, including minimizing false positives and improving assay conditions. SAMDI Tech will become part of Charles River's Discovery and Safety Assessment segment, expected to augment their comprehensive library of drug discovery solutions.

Charles River Laboratories (NYSE: CRL) has partnered with Rznomics Inc. to utilize its expertise in adenoviral vector production, facilitating the clinical trials of RZ-001, an RNA-based gene therapy targeting hepatocellular carcinoma (HCC). RZ-001, the first ribozyme-based therapy approved by the FDA, aims to treat liver cancer, which accounts for 80% of primary liver cancer cases worldwide. Following its FDA IND approval in October, Rznomics is set to initiate a Phase I/IIa clinical study internationally and in Korea. This collaboration enhances Charles River's established capabilities in gene therapy and manufacturing services, promoting effective clinical development.

Charles River Laboratories (NYSE:CRL) has launched the CliniPrime Fresh Leukopak, a GMP-compliant cellular starting material aimed at accelerating clinical trials and commercialization of advanced therapies. This initial product addresses the critical need for ready access to cGMP-enabled leukocyte materials, reducing client investment and risk. The CliniPrime suite features standardized production processes and complements existing offerings, such as GMPrime products and HemaPrime cellular products. Charles River, with over 40 years in cellular products, continues to support leading developers and researchers in the field.

Charles River Laboratories (NYSE: CRL) announces the launch of its eXpDNA plasmid platform during Phacilitate Advanced Therapies Week from January 17-20, 2023 in Miami, FL. This platform enhances plasmid development and production efficiency, reducing timelines to five weeks for High Quality plasmids and ten weeks for GMP plasmids. It builds on the company's vast experience in biologics testing, supporting multiple advanced therapy clients across various applications. Notable presentations will occur on January 18 and January 19.

Charles River Laboratories (NYSE: CRL) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10 at 10:30 a.m. PST (1:30 p.m. EST). The presentation will cover strategic focuses, business developments, and recent trends. Investors can access a live webcast through the Investor Relations section of their website, with a replay available for two weeks afterward. Charles River provides vital products and services to pharmaceutical and biotechnology firms, aiding in research and drug development.

Arlington Capital Partners has acquired Charles River Laboratories' Avian Vaccine Services business, establishing a new entity called AVS Bio. This company will operate independently and cater to the biologic manufacturing market. AVS Bio is a leader in supplying specific pathogen-free eggs and laboratory products essential for vaccine development and manufacturing. With approximately 250 employees across over 20 facilities in the US and Europe, AVS Bio aims to expand through new product development and strategic acquisitions. The acquisition signals Arlington's focus on mission-critical inputs in the biologic sector.

Charles River Laboratories (NYSE: CRL) has re-appointed Dr. Craig B. Thompson to its Board of Directors. Dr. Thompson, a former President and CEO of Memorial Sloan-Kettering Cancer Center, served on Charles River's board from 2013 to 2018. His expertise in immuno-oncology and leadership in healthcare will enhance the board's strategic direction. Dr. Thompson aims to support Charles River's mission in drug research and development. His extensive background includes leadership roles in prominent medical institutions and significant contributions to cancer research.

Charles River Laboratories (NYSE: CRL) has launched the Endosafe® Nexus 200™, a robotic endotoxin testing system designed to enhance laboratory productivity. This system enables efficient testing of undiluted and complex samples, leveraging Endosafe Limulus Amebocyte Lysate (LAL) cartridge technology. Key benefits include a reduction in product lead times by 60-70%, minimized human error, and improved data management through integration with Laboratory Information Management Systems (LIMS). This launch addresses the growing demand for high-throughput automated solutions in pharmaceutical manufacturing.